US SEC Filing Intelligence

New Federal Contractors — March 28, 2026

CGI Federal Inc., a Timken subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with $523M potential value through options to 2030, signaling bullish momentum in federal IT contracting. No outlays yet but 47 subawards at $15M indicate early subcontracting activity. Investors gain exposure to long-duration gov IT spend via performance-driven upside.

Significant Contract Modifications ($10M+) — March 28, 2026

A single significant $108M contract modification awarded to CGI Federal Inc. (Timken subsidiary) for EPA IT enterprise development signals strong federal demand in IT services, with potential expansion to $523M via options through 2030. This bullish development underscores GSA's reliance on cost-plus structures for environmental agency tech support. Investors should monitor option exercises amid execution risks from subawards and performance fees.

Contract Deobligations Alert — March 28, 2026

CGI Federal Inc., listed as a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT support, with potential expansion to $523M through options extending to 2030. No outlays yet signal early-stage execution, presenting bullish upside if options are exercised amid zero deobligations in this period. Investors should monitor performance evaluations and subaward costs for margin risks in govcon IT.

Contract Option Exercises — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M via options through 2030. This bullish signal provides multi-year revenue visibility in government IT services, though realization hinges on performance-based options and award fees. No outlays yet signal early-stage execution, warranting monitoring for margin impacts from $15M subawards.

Federal IT & Cybersecurity Contracts — March 28, 2026

CGI Federal Inc. secured a $108M obligated GSA delivery order for EPA IT enterprise development, with potential expansion to $522M through options by 2030, signaling strong federal demand in IT services. No funds outlayed yet, but long performance window to 2030 offers upside if options exercised. Investors should monitor performance evaluations amid subaward commitments and cost-plus structure risks.

Mega Contracts Monitor ($100M+) — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M through options to 2030. This bullish signal highlights strength in government IT services amid steady federal spending. Investors should monitor option exercises for revenue upside, tempered by execution risks from subawards and performance fees.

High-Value Federal Grants ($5M+) — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M through options exercisable to 2030. This signals strong demand for government IT services amid federal modernization pushes. Investors should monitor option exercises for revenue upside in the sector.

General Federal Contracts — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M through options to 2030. This bullish signal highlights sustained federal IT spending demand amid no outlays yet. Investors should monitor option exercises for revenue upside in govtech services.

Biotech Small-Cap Approvals — March 27, 2026

Two small-cap biotech ANDA approvals on March 24, 2026, for Ascent Pharms (Guanfacine Hydrochloride) and Zhejiang Jingxin (Ticagrelor) signal neutral generic market entries with no special designations or specified indications. Lacking premium positioning or expedited review, these offer limited differentiation amid standard generic competition. Investors should note steady commoditization in biotech small-caps but no material portfolio catalysts.

2 total filings

New Drug Approvals (Original) — March 27, 2026

FDA approved two generic ANDA products on March 24, 2026: Guanfacine Hydrochloride (Ascent Pharms Inc) and Ticagrelor (Zhejiang Jingxin), both under standard review with no special designations or specified indications. Neutral investment signals prevail due to generic nature and lack of differentiation or market details. Pattern indicates routine generic pipeline progress without material sector disruption or premium opportunities.

2 total filings

Federal Construction & Infrastructure Contracts — March 27, 2026

Three bullish federal contracts totaling $472M signal sustained U.S. government demand for construction in infrastructure resilience, embassy facilities, and disaster recovery across DOI, DOS, and DHS. Full base+options obligations provide revenue visibility to 2027 for Tutor Perini ($117M), Caddell ($168M), and BWI TPC JV ($187M near-complete), though firm-fixed-price terms and low aggregate outlays (~40%) flag execution risks. Cross-pattern: Full/open awards to non-small contractors highlight competitive strength in NAICS 236220/237990, with phased/hurricane work priming follow-ons.

3 total filings

DHS Homeland Security Contracts — March 27, 2026

Tutor Perini Corporation secured a $117M fully obligated firm fixed price contract from the U.S. Coast Guard for San Juan hurricane rebuild, providing committed revenue visibility through 2027-12-30. This single large award signals bullish momentum for the company in DHS infrastructure but flags execution risks from cost overruns and zero outlays to date. Investors should monitor progress for portfolio exposure to construction firms with federal disaster recovery expertise.

VA Healthcare & Services Contracts — March 27, 2026

ThunderCat Technology, LLC, a SDVOSB, won a $221.9M obligated VA delivery order (base + options: $1.56B) for Intersystems IT software support, with $74M already outlayed, marking a major bullish signal for VA healthcare IT spending. Potential extension to 2030 offers substantial revenue upside if options exercised, though firm-fixed pricing introduces cost overrun risks. Single-contract concentration highlights targeted opportunities in SDVOSB-aligned VA procurements amid full-and-open competition.

HHS & Healthcare Contracts Intelligence — March 27, 2026

HHS's BARDA issued an $88.9M cost-plus-fixed-fee contract to nonprofit ATCC for biological sample storage/distribution in MCM evaluation, with performance through 2028-09-26 and only $4.8M outlayed to date, signaling sustained federal health R&D funding but neutral equity implications due to recipient's tax-exempt status. The full obligation including all options offers revenue visibility amid health preparedness priorities. Investors face execution risks from low early spend and long duration, with limited direct plays but potential sector spillover.

New Federal Contractors — March 27, 2026

This one-day snapshot reveals $1.25B in new federal contract obligations, dominated by bullish IT/services (49%) and construction/infrastructure (38%) awards, signaling robust demand amid fiscal year-end reporting. Leidos captures $146M across two long-term IT deals (IRS/FAA), while ThunderCat's $222M VA IT order offers $1.56B ceiling potential. Sustained multi-year commitments through 2037 underscore revenue visibility for select contractors, though firm-fixed-price structures flag margin risks on 80% of value.

10 total filings

Significant Contract Modifications ($10M+) — March 27, 2026

This single-day stream of 10 significant contract modifications (> $10M) totals $1.25B in obligations, with 8 bullish signals dominated by IT/services and construction sectors, signaling robust federal spending continuity. Leidos stands out with $146M across two awards, bolstering long-term revenue visibility through 2037. Firm fixed price structures prevalent (80% of contracts) introduce execution risks, but high outlays in several (e.g., 60-99%) indicate strong funding momentum.

10 total filings